PATIENTS AND METHODS
Twenty patients (13 male) were included in the study which had the approval of the hospital Ethics Committee. Clinical details are shown in table I. To be eligible for inclusion, each patient was required to have achieved cardiovascular stability such that the heart rate and arterial pressure had shown little variation during continuous monitoring in the preceding 1 h. Thirteen patients were receiving inotropic agents in the form of dopamine or digoxin alone or in combination, dopamine or dobutamine in combination with isosorbide dinitrate or dopamine combined with dobutamine, to achieve such cardiovascular stability (table I) . Another patient (14) who had previously had a bilateral adrenalectomy was receiving an infusion of adrenaline at the time of the study. All patients had been stabilized on the inotrope(s) before the study began and were not entered into the study unless the dose of these agents was stable. All patients who satisfied the criteria entered the trial in order of admission to the ITU. A tracheal tube was in situ in all patients; 19 patients were receiving intermittent positive pressure ventilation of the lungs (IPPV) and one patient (10) was breathing spontaneously with continuous positive airways pressure (CPAP) at the time of the study.
As an indicator of severity of sickness, APACHE II scores (Knaus et al., 1985) were calculated. The average APACHE II score of the patients studied on admission to the ITU was 24.2 (range 13-36), while the average score at the time of the study was 19.0 (range 8-32).
The study was double-blind. A member of the medical staff not involved in the study diluted cimetidine 200 mg or ranitidine 50 mg to 20 ml with normal saline. The syringes were randomly marked A or B. The code was not broken until the end of the study. As is the usual practice in this ITU, each patient had already received i.v. ranitidine 50 mg 8 hourly after admission to the ITU. The study was, therefore, commenced 8 h after the last dose of ranitidine.
When a patient satisfied the entrance criteria for the study, the following baseline haemodynamic data were recorded: mean arterial pressure (MAP), heart rate (HR), central venous pressure (CVP), mean pulmonary artery pressure (MPAP), pulmonary artery wedge pressure (PAWP) and cardiac output (CO Systemic arterial pressure was monitored by percutaneous radial artery, catheterization and pulmonary artery pressure by a triple lumen flow directed pulmonary artery catheter (American Edwards Laboratory). The electrocardiograph (ECG), HR, MAP and MPAP were monitored continuously (Simonsen and Weel System, 8000 series) using Medex MX800 pressure transducers. Cardiac output was calculated by the thermodilution technique, using a cardiac output computer (952OA American Edwards Laboratory).
Following the recording of baseline data, the contents of syringe A (20 ml) were administered over a 2-min period by injection to the right atrium via the proximal lumen of the pulmonary artery catheter. HR and MAP only were recorded 1 min after the beginning of the injection and also at 2 min, when the injection was complete. The same recordings were also made at 3, 5, 10 and 15 min after commencement of the injection, together with MPAP, PAWP, CVP and CO. No other drug was administered during the 15 min period of study.
Eight hours later, syringe B was administered, the procedure being the same as for syringe A. However, if the patient's condition had changed significantly, the study was discontinued and, haemodynamic status permitting, was re-initiated the following day with two new preparations of histamine H 2 -receptor antagonist. Each patient, therfore, served as his own control. The haemodynamic measurements recorded at each time period were compared with baseline values. The Wilcoxon sign rank test was used for comparison of each result with baseline values and was also used to compare the changes in haemodynamic variables after cimetidine and ranitidine at each time interval. A two-tailed test of significance was used.
RESULTS
The mean values for each haemodynamic variable studied are summarized in tables II and III. Cimetidine i.v. was associated with significant decreases in MAP at 1 min (P < 0.01), 2 min (P < 0.01), 3 min (P < 0.01) and 5 min (P < 0.01) and significant decreases in derived SVR at 3 min (P < 0.01), 5 min (P < 0.01) and 10 min (P < 0.05).
I.v. ranitidine was followed by significant decreases in MAP at 1 min (P < 0.05) and 2 min (P < 0.01); the decrease in MAP at 3 min did not achieve statistical significance. The mean derived SVR decreased after the injection of ranitidine, but the difference from baseline did not achieve statistical significance.
The effect of cimetidine on MAP was longer lasting than that of ranitidine ( fig. 1) . Thus MAP had almost returned to baseline values 5 min after commencement of ranitidine administration, but not until 10 min after commencement of cimetidine injection.
There were no significant changes in mean values for HR, MPAP, PAWP, CO, or PVR after either of the drugs. Cardiac rhythm did not vary in any patient.
A marked between-patient variation was found in both the MAP ( fig. 1 ) and SVR changes following cimetidine or ranitidine. The variation appeared to be greater widi cimetidine. For example, in 13 patients die decrease in MAP was greater dian 10 mm Hg after cimetidine, but in only two patients was this so after ranitidine. In all patients, the hypotensive effect occurred in the presence of minimal changes in cardiac output.
Application of the Wilcoxon sign rank test to a comparison of the change in MAP (AMAP) within each individual patient following cimetidine and ranitidine showed a significantly greater decrease with cimetidine at 2, 3 and 5 min (P < 0.01). In each of the 11 patients in whom AMAP was greater than 5 mm Hg from baseline during or after injection of both agents, the decrease was greater following cimetidine. Similarly, the Wilcoxon sign rank test showed that the decrease in SVR was significantly greater following cimetidine compared widi ranitidine at 3 and 5 min (P < 0.01). Whilst cimetidine almost invariably was associated widi an initial decrease in SVR, ranitidine was less predictable.
In no patient did die decrease in MAP cause circulatory embarrassment such diat dierapeutic intervention was required. By die end of the study period (15 min), no MAP was greater dian 4 mm Hg below baseline value and both groups had 13 patients with MAP above baseline by this time (fig-1 ).
DISCUSSION
In critically ill patients, the i.v. administration of cimetidine produced a significant, transient de- crease in MAP of about 10 mm Hg. This was the result of systemic vasodilatation; no change in CO was seen during the 15-min period of study, but SVR decreased markedly (table II) . Ranitidine i.v. decreased MAP in some patients, also by a vasodilatory mechanism (table III) . The incidence and extent of this decrease in MAP was significantly less after ranitidine than cimetidine ( fig. 1) .
No patient required treatment for the hypotensive effects of these agents. This study demonstrated considerable variation in the cardiovascular response to both cimetidine and ranitidine between individual critically ill patients. Standard deviations of the mean MAP and SVR at regular intervals after both drugs were large (tables II, III). This variation is almost inevitable when studying critically ill patients and it is a limiting factor in any study performed in this setting. All the patients studied were undoubtedly suffering from severe myocardial depression, usually as a result of septicaemia; several were receiving inotropic agents i.v. (table I) . Dopamine is usually the first inotrope we use, especially if renal function is threatened. Dobutamine, up to a dose of 15 ^g kg" 1 min" 1 , is introduced if an adequate CO is not obtained witfi dopamine 15 ug kg" 1 min "'. If both these agents do not produce the required response, adrenaline i.v. is added. It is not uncommon for these inotropes to be continued for several days while recovery of myocardial function subsequent to appropiate antibiotic therapy to control the septicaemia occurs. It was during this period of relative CVS stability that this study was carried out, as we believed it was less likely that the patient's unstable condition could have contributed to the results obtained. In addition, to prevent the influence of any other drugs (eg. antibiotics) on the CVS recordings, these were not given during the period of study. Breuer and colleagues (1985) have compared the haemodynamic effects of cimetidine and ranitidine in ITU patients in the same dosage and with the same rate of administration as was used in this study, but without the use of a pulmonary artery catheter. A similar effect on MAP was observed, although the degree of change was less than that seen in this study. This may reflect a difference in the degree of morbidity of the patients between the two studies.
Iberti and colleagues (1986) studied only cimetidine in a larger dose (300 mg). When it was administered over a 2-min period, a proportionately greater decrease in MAP in comparison with our findings was observed, again as a result of systemic vasodilatation.
When cimetidine 200 mg was given as an i.v. bolus to patients on cardiopulmonary bypass, the MAP decreased for 3-5 min (Heining et al., 1983) . As the myocardial effect on arterial pressure is excluded during cardiopulmonary bypass, the decrease in MAP must have been caused by a decrease in SVR.
In healthy volunteers, neither cimetidine 3.5 mg kg" 1 nor ranitidine 1.5 mg kg" 1 given i.v. over 5 min, caused a significant effect on the indices of cardiac function measured non-invasively (Barbat and Warrington, 1980) . Even a large dose of cimetidine (800 mg) given i.v. over 1 min did not affect arterial pressure in healthy subjects, although it did increase heart rate (Boyce, 1981) . Lee and colleagues (1981) gave cimetidine 400 mg and found a transient but significant decrease in systemic and pulmonary artery pressures in all subjects tested, the changes being more marked in patients with chronic obstructive airways disease than in healthy controls.
It is not difficult to imagine why severe hypotension following i.v. cimetidine has been reported (Mahon and Kolton, 1978; Selby, 1981; Hammond and Ware, 1983) . One patient in the study of Iberti and others (1986) had a decrease in MAP from 80 mm Hg to 36 mm Hg following cimetidine 300 mg; volume therapy was required to restore the haemodynamic values. No patient in our study had a decrease in MAP of more than 24 mm Hg after the smaller dose of cimetidine (200 mg), while the greatest decrease in MAP following ranitidine was 15 mm Hg.
In addition to hypotension, there have been reports of other cardiovascular effects of histamine Hj-receptor antagonist therapy. Severe bradycardia has been associated with both cimetidine i.v. (Jefferys and Vale, 1978; Ligumsky, Shochina and Rachmilewitz, 1978) and ranitidine i.v. (Camarri et al., 1982) . In addition, i.v. cimetidine has been incriminated in the aetiology of ventricular arrhythmias (MacMahon, Bakshi and Walsh, 1981; Watson, Watson and Keogh, 1982) and asystole (Cohen et al., 1979) . Such effects were not observed in this study, but the number of patients was small. Also the inotropic infusions which many of the patients were receiving obscured this effect. The heart and peripheral blood vessels possess H,-receptors (Anonymous, 1982; Thomas and Misiewicz, 1984) and it is presumed that any change in cardiac rate or rhythm is mediated through these receptors.
Whilst previous studies have shown a decrease in PVR (Lee et al., 1981; Iberti et al., 1986) and mild increases in HRand CO (Boyce, 1981; Iberti et al., 1986) , these changes were not observed in this study. Iberti and co-workers (1986) suggested that the usual cardiac compensatory mechanisms that occur following acute vasodilatation (increased HR and CO), are not seen in very ill patients. Certainly, in the healthy volunteers in the study by Boyce (1981) the HR increased significantly with no alteration in arterial pressure following a large bolus dose of cimetidine (800 mg) i.v., suggesting an appropriate cardiovascular response to vasodilatation.
In this study every patient was given a dose of cimetidine 200 mg or ranitidine 50 mg, regardless of weight, age, renal or hepatic function. Thus, blood concentrations could have varied markedly following this fixed dose, which was chosen to be consistent with current clinical practice on this ITU. This factor may also explain in part the wide variation in the changes in MAP and SVR. However, as the cardiovascular effects were so short-lasting, any influence of delayed elimination of these agents on the cardiovascular measurements must have been minimal.
Even when given relatively slowly (over 2 min), i.v. cimetidine 200 mg and ranitidine 50 mg caused significant hypotension in critically ill patients and it would probably be more prudent in the patient with cardiovascular impairment to give such a dose over at least 10 min.
The data sheet for Zantac (ranitidine) injection advises that 50 mg should be given over only 1 min. Although ranitidine caused less hypotension than cimetidine, two patients had decreases in MAP of up to 15 mm Hg with i.v. ranitidine 50 mg over a 2-min period. Consequently, the possibility of hypotension following ranitidine as well as cimetidine in critically ill patients should be remembered, especially if the drug is given over only 1 min. We believe that cimetidine should be diluted and infused i.v. over at least 10 min as cimetidine is more likely than ranitidine to produce an adverse haemodynamic response.
